Key Events This Week
27 Jul: Stock opens week at Rs.4,690.15, up 1.57%
28 Jul: Q1 FY27 results reveal strong profit growth, stock rises 0.33%
29 Jul: Quarterly turnaround confirmed, stock gains 1.04%
30 Jul: Continued positive momentum, stock up 0.93%
31 Jul: Week closes at Rs.4,822.80, up 0.49%
Monday, 27 July 2026: Strong Start Amid Broad Market Rally
Pfizer Ltd began the week on a positive note, closing at Rs.4,690.15, a gain of 1.57% from the previous Friday’s close of Rs.4,617.70. This outpaced the Sensex’s 1.05% rise to 36,207.16, signalling early investor confidence. The volume was moderate at 792 shares, reflecting steady interest as the broader market rallied.
Tuesday, 28 July 2026: Quarterly Results Spark Optimism
On 28 July, Pfizer announced its Q1 FY27 results, revealing strong profit growth that somewhat masked valuation concerns. The stock edged up 0.33% to close at Rs.4,705.60 despite a slight Sensex decline of 0.14%. The results highlighted record net sales of ₹653.17 crores and a PBDIT of ₹247.56 crores, with operating margins expanding to 37.90%. This robust financial performance provided a foundation for the stock’s resilience amid mixed market conditions.
Rising fast and still accelerating! This Small Cap from FMCG sector is riding pure momentum right now. Jump in before the rally reaches its peak!
- - Accelerating price action
- - Pure momentum play
- - Pre-peak entry opportunity
Wednesday, 29 July 2026: Financial Turnaround Confirmed
Pfizer’s positive momentum continued on 29 July, with the stock gaining 1.04% to close at Rs.4,754.75, outperforming the Sensex’s 1.02% rise to 36,524.95. The company reported a strong quarterly financial turnaround, with net profit after tax surging to ₹204.47 crores and EPS rising to ₹44.69. The balance sheet showed strength with cash reserves at ₹3,110.76 crores and improved debtor turnover of 13.86 times. Despite these fundamentals, the Mojo Grade was downgraded to Sell, reflecting market caution possibly linked to valuation and sector risks.
Thursday, 30 July 2026: Steady Gains Amid Market Stability
On 30 July, Pfizer’s stock price rose 0.93% to Rs.4,799.05, marginally outperforming the Sensex’s 0.05% increase. The relatively low volume of 429 shares suggested a consolidation phase following the strong quarterly news. The company’s operational efficiency and margin expansion continued to underpin investor sentiment, supporting the stock’s steady climb.
Friday, 31 July 2026: Week Closes on a Positive Note
Pfizer closed the week at Rs.4,822.80, up 0.49% on the day and marking a 4.44% gain for the week. The Sensex also advanced 0.39% to 36,684.83. The stock’s consistent gains throughout the week reflect investor recognition of the company’s improved financial trajectory, despite the cautious Mojo Grade downgrade. Volume picked up to 761 shares, indicating renewed interest as the week ended.
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-07-27 | Rs.4,690.15 | +1.57% | 36,207.16 | +1.05% |
| 2026-07-28 | Rs.4,705.60 | +0.33% | 36,155.32 | -0.14% |
| 2026-07-29 | Rs.4,754.75 | +1.04% | 36,524.95 | +1.02% |
| 2026-07-30 | Rs.4,799.05 | +0.93% | 36,541.96 | +0.05% |
| 2026-07-31 | Rs.4,822.80 | +0.49% | 36,684.83 | +0.39% |
Key Takeaways
Strong Quarterly Performance: Pfizer’s record net sales of ₹653.17 crores and net profit of ₹204.47 crores highlight a significant turnaround in financial health, supported by improved operational margins and cash flow metrics.
Stock Outperformance: The stock’s 4.44% weekly gain notably outpaced the Sensex’s 2.39% rise, reflecting investor confidence in Pfizer’s growth trajectory despite broader market volatility.
Mojo Grade Downgrade: The downgrade to Sell with a Mojo Score of 48.0 signals market caution, likely due to valuation concerns and sector-specific risks, underscoring the need for careful monitoring.
Sectoral Context: Operating in the competitive Pharmaceuticals & Biotechnology sector, Pfizer’s improved financials demonstrate effective management but also highlight the challenges of sustaining growth amid regulatory and innovation pressures.
Why settle for Pfizer Ltd.? SwitchER evaluates this small-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Conclusion
Pfizer Ltd’s week was characterised by a strong financial turnaround and steady stock gains that outperformed the broader market. The company’s record quarterly results and improved operational metrics underpin this positive momentum. However, the Mojo Grade downgrade to Sell reflects underlying valuation and sector risks that temper enthusiasm. Investors should consider Pfizer’s robust cash position and improving trend alongside cautious market sentiment. Overall, the week’s developments mark a pivotal phase for Pfizer, balancing promising fundamentals with prudent caution.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
